Takeda Pharmaceutical Co. Ltd. agreed to acquire Intellikine Inc., of La Jolla, Calif., for $190 million up front, with $120 million in potential clinical milestone payments. Intellikine's assets include small molecule kinase inhibitors of the phoshoinositide-3 kinase (PI3K 1) and mammalian target of rapamycin (mTOR2) pathways with ongoing Phase I trials in solid tumors and hematologic malignancies.